Novel Uses of Neuraminidase Inhibitors in Infectious Diseasess

Abstract

The present invention relates to methods of decreasing the infectivity, morbidity and rate of mortality, in treating diseases associated with a variety of pathogenic organisms, specifically diseases involving one or more pathogens that require neuraminidase as a virulence factor. In addition, the present invention uses biology based therapy to treat neuraminidase dependent infections or diseases dependent on sialic acid metabolism.

1 . A method for inhibiting neuraminidase dependent bacterial infections that are not viral generated dependent infections, from a disease-causing microorganism dependent on sialic acid metabolism, comprising administering to an animal in need thereof a therapeutically effective amount of a composition comprising one or more compounds, wherein one of the compounds comprises neuraminidase inhibitors. 
     
     
         2 . The method of  claim 1 , wherein the neuraminidase inhibitor is selected from the group consisting of zanamivir, oseltamivir, rimantadine, rimantadine hydrochloride, amantadine, ribavirin and the like and any drug that are synthetic sialic acid analogs that can inhibit action of viral, bacterial and eukaryotic neuraminidases. 
     
     
         3 . The method of  claim 1 , wherein the disease-causing microorganism causes infectious diseases selected from the group consisting of parvoviral enteritis, canine kennel cough, feline upper respiratory infections, and feline nephritis secondary to  E. coli.    
     
     
         4 . A method for treating neuraminidase dependent bacterial infections that are not viral generated dependent infections, from a disease-causing microorganism dependent on sialic acid metabolism, comprising administering to an animal in need thereof a therapeutically effective amount of a composition comprising one or more compounds, wherein one of the compounds comprises neuraminidase inhibitors. 
     
     
         5 . The method of  claim 4 , wherein the neuraminidase inhibitor is selected from the group consisting of zanamivir, oseltamivir, rimantadine, rimantadine hydrochloride, amantadine, ribavirin and the like and any drug that are synthetic sialic acid analogs that can inhibit action of viral, bacterial and eukaryotic neuraminidases. 
     
     
         6 . The method of  claim 4 , wherein the disease-causing microorganism causes infectious diseases selected from the group consisting of parvoviral enteritis, canine kennel cough, feline upper respiratory infections, and feline nephritis secondary to  E. coli.    
     
     
         7 . A method of using an antiviral drug for human influenza to treat neuraminidase dependent bacterial infections, that are not viral generated dependent infections, superinfections and coinfections which do not involve the human influenza virus A and/or B, in clinical veterinary medicine, comprising administering to an animal in need thereof a therapeutically effective amount of a composition comprising one or more compounds, wherein one of the compounds comprises neuraminidase inhibitors. 
     
     
         8 . The method of  claim 7 , wherein the neuraminidase inhibitor is selected from the group consisting of zanamivir, oseltamivir, rimantadine, rimantadine hydrochloride, amantadine, ribavirin and the like and any drug that are synthetic sialic acid analogs that can inhibit action of viral, bacterial and eukaryotic neuraminidases.